Human Microbiome Market Analysis

Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs)

The probiotics segment is set to gain the largest market share of 40% by the year 2037. The increasing prevalence of digestive diseases across the globe is driving the demand for probiotics as some probiotics can improve the immune system, reduce inflammation, and may even lower cholesterol. According to statistics, more than 35% of people around the world experience persistent digestive issues. It is assessed that live bacteria and yeasts called probiotics are beneficial to health, particularly the digestive system, and have been proven to be successful in treating common symptoms, including bloating, stomach pain, and diarrhea.

The drugs segment is counted to pool in the highest revenue in the given period owing to the rising investment in the field of live biotherapeutics which is envisaged to develop pharmacologic treatments for a range of diseases.

Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases)

The gastrointestinal diseases segment is speculated to garner a significant growth rate of around 46% through 2037, as the development and treatment of gastrointestinal illnesses are significantly influenced by the human microbiome. Gut health could be improved and the risk of gastrointestinal disorders could be decreased with probiotics, prebiotics, and other microbiome-targeted medicines. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments:

Product	Probiotics Prebiotics Diagnostic Tests Drugs
Disease Type	Infectious Disease Obesity Diabetes Gastrointestinal Diseases Cancer Cardiovascular Diseases
Organism Type	Aerobic Organisms Obligate & Facultative Anaerobes Genetically Engineered Strains BSL-2 & Spore-Forming Species
Application	Therapeutics Diagnostics
Technology	Genomics Proteomics Metabolomics

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of human microbiome is estimated at USD 561.5 million.

The human microbiome market size was over USD 445.92 million in 2024 and is projected to cross USD 11.73 billion by the end of 2037, witnessing more than 32.2% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of the human microbiome in health and disease and increasing research on its major impact on human physiology, metabolic and immune functions will boost the market growth.

North America is poised to account for the largest share of 35% by 2037, driven by rising pet adoption in the region.

The major players in the market include Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D Pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.

Human Microbiome Market Analysis